Literature DB >> 23418294

Relationship of delayed enhancement by magnetic resonance to myocardial perfusion by positron emission tomography in hypertrophic cardiomyopathy.

Paco E Bravo1, Stefan L Zimmerman, Hong-Chang Luo, Iraklis Pozios, Mahadevan Rajaram, Aurélio Pinheiro, Charles Steenbergen, Ihab R Kamel, Richard L Wahl, David A Bluemke, Frank M Bengel, M Roselle Abraham, Theodore P Abraham.   

Abstract

BACKGROUND: Presence of delayed enhancement (DE) on cardiac magnetic resonance (CMR) is associated with worse clinical outcomes in hypertrophic cardiomyopathy. We investigated the relationship between DE on CMR and myocardial ischemia in hypertrophic cardiomyopathy. METHODS AND
RESULTS: Hypertrophic cardiomyopathy patients (n=47) underwent CMR for assessment of DE and vasodilator stress ammonia positron emission tomography to quantify myocardial blood flow and coronary flow reserve. The summed difference score for regional myocardial perfusion was also assessed. Patients in the DE group (n=35) had greater left ventricular wall thickness (2.09±0.44 versus 1.78±0.34 cm; P=0.03). Stress myocardial blood flow (2.25±0.46 versus 1.78±0.43 mL/min per gram; P=0.01) and coronary flow reserve (2.78±0.32 versus 2.01±0.52; P<0.001) were significantly lower in DE-positive patients. Summed difference score (7.3±6.6 versus 0.9±1.4; P<0.0001) was significantly higher in patients with DE. A coronary flow reserve <2.00 was seen in 18 patients (51%) with DE but in none of the DE-negative patients (P<0.0001). CMR and positron emission tomography showed visually concordant DE and regional myocardial perfusion abnormalities in 31 patients and absence of DE and perfusion defects in 9 patients. Four DE-positive patients demonstrated normal regional myocardial perfusion, and 3 DE-negative patients had (apical) regional myocardial perfusion abnormalities.
CONCLUSIONS: We found a close relationship between DE by CMR and microvascular function in most of the patients studied. However, a small proportion of patients had DE in the absence of perfusion abnormalities, suggesting that microvascular dysfunction and ischemia are not the sole causes of DE in hypertrophic cardiomyopathy patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23418294      PMCID: PMC4124735          DOI: 10.1161/CIRCIMAGING.112.000110

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  38 in total

1.  The mitochondrial origin of postischemic arrhythmias.

Authors:  Fadi G Akar; Miguel A Aon; Gordon F Tomaselli; Brian O'Rourke
Journal:  J Clin Invest       Date:  2005-11-10       Impact factor: 14.808

2.  Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging.

Authors:  G D Hutchins; M Schwaiger; K C Rosenspire; J Krivokapich; H Schelbert; D E Kuhl
Journal:  J Am Coll Cardiol       Date:  1990-04       Impact factor: 24.094

Review 3.  Molecular basis of arrhythmias.

Authors:  Manish Shah; Fadi G Akar; Gordon F Tomaselli
Journal:  Circulation       Date:  2005-10-18       Impact factor: 29.690

4.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy.

Authors:  B J Maron; J K Wolfson; S E Epstein; W C Roberts
Journal:  J Am Coll Cardiol       Date:  1986-09       Impact factor: 24.094

5.  Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy.

Authors:  M Tanaka; H Fujiwara; T Onodera; D J Wu; M Matsuda; Y Hamashima; C Kawai
Journal:  Circulation       Date:  1987-06       Impact factor: 29.690

6.  Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging.

Authors:  Steffen E Petersen; Michael Jerosch-Herold; Lucy E Hudsmith; Matthew D Robson; Jane M Francis; Helen A Doll; Joseph B Selvanayagam; Stefan Neubauer; Hugh Watkins
Journal:  Circulation       Date:  2007-04-23       Impact factor: 29.690

7.  Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries.

Authors:  B J Maron; S E Epstein; W C Roberts
Journal:  Am J Cardiol       Date:  1979-06       Impact factor: 2.778

8.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Iacopo Olivotto; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Paolo G Camici
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

9.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance.

Authors:  James C C Moon; William J McKenna; Jane A McCrohon; Perry M Elliott; Gillian C Smith; Dudley J Pennell
Journal:  J Am Coll Cardiol       Date:  2003-05-07       Impact factor: 24.094

10.  Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy.

Authors:  Iacopo Olivotto; Franco Cecchi; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Francesca Girolami; Francesca Torricelli; Paolo G Camici
Journal:  J Am Coll Cardiol       Date:  2006-03-07       Impact factor: 24.094

View more
  18 in total

1.  Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype?

Authors:  Paco E Bravo; Hong-Chang Luo; Iraklis Pozios; Stefan L Zimmerman; Celia Pamela Corona-Villalobos; Lars Sorensen; Ihab R Kamel; David A Bluemke; Richard L Wahl; M Roselle Abraham; Theodore P Abraham
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-06-14       Impact factor: 6.875

Review 2.  Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives.

Authors:  Georgios K Efthimiadis; Efstathios D Pagourelias; Thomas Gossios; Thomas Zegkos
Journal:  World J Cardiol       Date:  2014-02-26

3.  Myocardial perfusion reserve quantified by cardiac magnetic resonance imaging is associated with late gadolinium enhancement in hypertrophic cardiomyopathy.

Authors:  Daisuke Tezuka; Hisanori Kosuge; Masahiro Terashima; Nozomu Koyama; Tadashi Kishida; Yuko Tada; Jun-Ichi Suzuki; Tetsuo Sasano; Takashi Ashikaga; Kenzo Hirao; Mitsuaki Isobe
Journal:  Heart Vessels       Date:  2017-11-22       Impact factor: 2.037

4.  Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy.

Authors:  Dai-Yin Lu; Hulya Yalçin; Fatih Yalçin; Min Zhao; Sanjay Sivalokanathan; Ines Valenta; Abdel Tahari; Martin G Pomper; Theodore P Abraham; Thomas H Schindler; M Roselle Abraham
Journal:  Am J Cardiol       Date:  2018-02-06       Impact factor: 2.778

Review 5.  Role of PET to evaluate coronary microvascular dysfunction in non-ischemic cardiomyopathies.

Authors:  Paco E Bravo; Marcelo F Di Carli; Sharmila Dorbala
Journal:  Heart Fail Rev       Date:  2017-07       Impact factor: 4.214

6.  Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in hypertension and associated with left ventricular remodeling.

Authors:  Shuli Wang; Hongjie Hu; Minjie Lu; Arlene Sirajuddin; Jinghui Li; Jing An; Xiuyu Chen; Gang Yin; Tian Lan; Linlin Dai; Yan Zhang; Xiaorong Yin; Lei Song; Aimin Dang; Peter Kellman; Andrew E Arai; Shihua Zhao
Journal:  Eur Radiol       Date:  2017-04-24       Impact factor: 5.315

7.  Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?

Authors:  Paco E Bravo
Journal:  J Nucl Cardiol       Date:  2018-05-14       Impact factor: 5.952

8.  Comparison of Outcomes in Patients With Nonobstructive, Labile-Obstructive, and Chronically Obstructive Hypertrophic Cardiomyopathy.

Authors:  Iraklis Pozios; Celia Corona-Villalobos; Lars L Sorensen; Paco E Bravo; Marco Canepa; Chiara Pisanello; Aurelio Pinheiro; Veronica L Dimaano; Hongchang Luo; Zeina Dardari; Xun Zhou; Ihab Kamel; Stefan L Zimmerman; David A Bluemke; M Roselle Abraham; Theodore P Abraham
Journal:  Am J Cardiol       Date:  2015-06-26       Impact factor: 2.778

Review 9.  Tissue-level inflammation and ventricular remodeling in hypertrophic cardiomyopathy.

Authors:  Richard C Becker; A Phillip Owens; Sakthivel Sadayappan
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

10.  Machine Learning Methods for Identifying Atrial Fibrillation Cases and Their Predictors in Patients With Hypertrophic Cardiomyopathy: The HCM-AF-Risk Model.

Authors:  Moumita Bhattacharya; Dai-Yin Lu; Ioannis Ventoulis; Gabriela V Greenland; Hulya Yalcin; Yufan Guan; Joseph E Marine; Jeffrey E Olgin; Stefan L Zimmerman; Theodore P Abraham; M Roselle Abraham; Hagit Shatkay
Journal:  CJC Open       Date:  2021-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.